eicosapentaenoic acid ethyl ester has been researched along with alprostadil in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, M | 1 |
| Gose, T; Kamo, S; Nakanishi, T; Otake, K; Shimada, H; Tamai, I | 1 |
1 trial(s) available for eicosapentaenoic acid ethyl ester and alprostadil
| Article | Year |
|---|---|
The NMatrix, a new method of presenting statistics, displays the characteristics of medicines with similar effects used in the treatment of lumbar spinal stenosis concisely and clearly, facilitating the selection of appropriate medications.
Topics: Aged; Aged, 80 and over; alpha-Cyclodextrins; Alprostadil; Decision Making; Eicosapentaenoic Acid; Epoprostenol; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; Pain Measurement; Platelet Aggregation Inhibitors; Sciatica; Spinal Stenosis; Succinates; Treatment Outcome | 2015 |
1 other study(ies) available for eicosapentaenoic acid ethyl ester and alprostadil
| Article | Year |
|---|---|
Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3.
Topics: Administration, Oral; Alprostadil; Animals; Biological Transport; Colon; Dinoprostone; Eicosapentaenoic Acid; Female; Gastric Mucosa; HEK293 Cells; Humans; Kidney; Kinetics; Liver-Specific Organic Anion Transporter 1; Lung; Mice, Knockout; Mutation; Organic Anion Transporters; Tissue Distribution; Transfection | 2016 |